Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom The above ...
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks. Photo: Javier Zayas Photography/Getty Images Medical device ...
Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...
Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...
Dexcom G5 Mobile CGM System keeps glucose data flowing every five minutes for people living with diabetes who still rely on this legacy sensor platform. Anyone holding Dexcom Inc. stock (NASDAQ: DXCM, ...
When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results